You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

B-line

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Diffuse Large B-cell Lymphoma Trial in Changchun (Mitoxantrone HCl liposome injection, RiTUXimab Injection, Cyclophosphamid)

Not yet recruiting
  • Diffuse Large B-cell Lymphoma
  • Mitoxantrone hydrochloride liposome injection
  • +4 more
  • Changchun, Jilin, China
    The First Bethune Hospital of Jilin University
Aug 15, 2023

DLBCL, Not Otherwise Specified Trial in Chongqing (selinexor)

Recruiting
  • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • Chongqing, Chongqing, China
    Chongqing University Cancer Hospital
Mar 27, 2023

Diffuse Large B Cell Lymphoma Trial (Epcoritamab, Lenalidomide)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • (no location specified)
Jan 20, 2023

OR Regimen Refractory Marginal Zone Lymphoma Trial (obrutinib, rituximab)

Not yet recruiting
  • OR Regimen Refractory Marginal Zone Lymphoma
  • obrutinib, rituximab
  • (no location specified)
Nov 12, 2023

Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma Trial in China (Relmacabtagene

Not yet recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • +3 more
  • Relmacabtagene Autoleucel
  • +2 more
  • Guangzhou, Guangdong, China
  • +12 more
Oct 24, 2023

B-cell Lymphoma Trial in Beijing (Relmacabtagene Autoleucel, Fludarabine, Cyclophosphamide)

Not yet recruiting
  • B-cell Lymphoma
  • Relmacabtagene Autoleucel
  • +2 more
  • Beijing, Beijing, China
  • +1 more
Oct 19, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (BL-B01D1, capecitabine, gemcitabine)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 31, 2023

High-risk Large B-cell Lymphoma (LBCL) Trial (Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine)

Not yet recruiting
  • High-risk Large B-cell Lymphoma (LBCL)
  • Axicabtagene Ciloleucel
  • +7 more
  • (no location specified)
Dec 13, 2022

TNBC - Triple-Negative Breast Cancer Trial (A1:SG with SHR3680, A2:SG, B1:SG with SHR1210)

Not yet recruiting
  • TNBC - Triple-Negative Breast Cancer
  • A1:SG with SHR3680
  • +7 more
  • (no location specified)
Jun 23, 2023

Metastatic Pancreatic Adenocarcinoma Trial (Avelumab and Pepinemab)

Recruiting
  • Metastatic Pancreatic Adenocarcinoma
  • Avelumab and Pepinemab
  • Rochester, New York
    University of Rochester Medical Center
Jan 19, 2023

HER2-positive Advanced Gastric Cancer Trial (trastuzumab, bevacizumab with paclitaxel (triple combination))

Not yet recruiting
  • HER2-positive Advanced Gastric Cancer
  • trastuzumab, bevacizumab with paclitaxel (triple combination)
  • (no location specified)
Dec 6, 2022

Lymphadenopathy Retroperitoneal, Stage II Testicular Seminoma Trial in Toronto (Robotic Retroperitoneal Lymph Node Dissection

Recruiting
  • Lymphadenopathy Retroperitoneal
  • Stage II Testicular Seminoma
  • Robotic Retroperitoneal Lymph Node Dissection (RPLND)
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
May 16, 2022

Hepatocellular Carcinoma Trial (Ezurpimtrostat, Atezolizumab, Bevacizumab)

Recruiting
  • Hepatocellular Carcinoma
  • Grenoble, France
    University Hospital
Dec 23, 2022

Non-small Cell Lung Adenocarcinoma, Squamous Cell Carcinoma of Lung Trial in Guangzhou (SI-B001, Docetaxel)

Not yet recruiting
  • Non-small Cell Lung Adenocarcinoma
  • Squamous Cell Carcinoma of Lung
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Jul 5, 2023

Non-Hodgkin Lymphoma, Large B-cell Lymphoma Trial in Palo Alto (Axicabtagene Ciloleucel)

Not yet recruiting
  • Non-Hodgkin Lymphoma
  • Large B-cell Lymphoma
  • Axicabtagene Ciloleucel
  • Palo Alto, California
    Stanford University
Mar 20, 2023

Advanced Adult Hepatocellular Carcinoma Trial in Chicago, Ann Arbor, Dallas (Cabozantinib)

Recruiting
  • Advanced Adult Hepatocellular Carcinoma
  • Chicago, Illinois
  • +3 more
Aug 15, 2022

Heart Failure Trial in Seoul (Lung ultrasound)

Recruiting
  • Heart Failure
  • Lung ultrasound
  • Seoul, Korea, Republic of
    Asan Medical Center
Apr 9, 2021

Metastatic Urothelial Carcinoma, Urothelial Tumors Trial (Coformulated favezelimab/pembrolizumab, Coformulated

Not yet recruiting
  • Metastatic Urothelial Carcinoma
  • Urothelial Neoplasms
  • Coformulated favezelimab/pembrolizumab
  • +3 more
  • (no location specified)
Apr 26, 2023

Hepatocellular Carcinoma, Cancer of Liver Trial (PXS-5505 and Atezolizumab and Bevacizumab)

Recruiting
  • Hepatocellular Carcinoma
  • Cancer of Liver
  • PXS-5505 and Atezolizumab and Bevacizumab
  • Rochester, New York
    University of Rochester
Nov 3, 2022

Renal Cell Carcinoma Trial in Houston (Ipilimumab, Nivolumab, Ciforadenant)

Not yet recruiting
  • Renal Cell Carcinoma
  • Houston, Texas
    M D Anderson Cancer Center
Aug 11, 2022

EBV-associated Lymphomas Trial ((Autologous monocyte-derived DCs pulsed with allogeneic EBV-transformed B-lymphoblastoid cell

Not yet recruiting
  • EBV-associated Lymphomas
  • (Autologous monocyte-derived DCs pulsed with allogeneic EBV-transformed B-lymphoblastoid cell line lysate
  • (no location specified)
May 31, 2023

Gastric Adenocarcinoma Trial in Guangzhou (Sintilimab, Ramucirumab, Cisplatin)

Active, not recruiting
  • Gastric Adenocarcinoma
  • Guangzhou, China
    Sun Yat-sen University Cancer Center
Oct 10, 2022

Follicular Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma Trial in New Haven, New Brunswick, Providence (Mosunetuzumab,

Recruiting
  • Follicular Lymphoma
  • +2 more
  • New Haven, Connecticut
  • +2 more
Jul 14, 2022

Unfit CLL Included in GIMEMA LLC1114 Trial Who Discontinued

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Observation
  • (no location specified)
Oct 12, 2023

Metastatic Gastric Cancer Trial in Zhengzhou (fruquintinib+toripalimab + SOX)

Recruiting
  • Metastatic Gastric Cancer
  • fruquintinib＋toripalimab + SOX
  • Zhengzhou, Henan, China
    The First Affiliated Hospital of Zhengzhou University
Aug 17, 2022